Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

About Us
We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

Our Technology
We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

Our Products

0

Employees

0

Patents and patent applications

0

Biosimilars under development

Fraudulent attempts to use Xbrane's name

We want to inform our customers, partners, and other stakeholders that we have become aware of fraudulent attempts to use Xbrane’s name, particularly fake recruitment services. We take the security of our customers and business relationships very seriously and, therefore, emphasize the importance of remaining vigilant.

Please note that Xbrane does not engage in external advertisements for recruitment purposes. Our official recruitment communication channels are limited to our website (https://www.xbrane.com), email addresses ending with @xbrane.com, and our company page on LinkedIn (https://www.linkedin.com/company/xbrane-bioscience-ab).

Interview with CEO Martin Åmark, October 2023

At Xbrane Biopharma

Press Releases

09 Jan 2025

Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

31 Dec 2024

XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

18 Dec 2024

Xbrane announces outcome of exercise of warrants of series TO1

02 Dec 2024

XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY

26 Nov 2024

Xbrane AB (publ) today announces that the company’s CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.

21 Nov 2024

XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES

19 Nov 2024

Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo®

31 Oct 2024

XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE

24 Oct 2024

Xbrane Biopharma releases Interim Report for January-September 2024